利用母体特征、生物标志物和估计胎盘体积进行早发型与晚发型子痫前期早孕期筛查
本研究为美国非选择性人群的前瞻性观察性非干预队列研究,纳入1288例孕11-13+6周超声检查者,最终1068例(82.99%)可分析。46例(4.3%)发生子痫前期,其中早发型13例(1.22%)、晚发型33例(3.09%)。联合母体特征、血清生物标志物和子宫动脉搏动指数筛查早发型子痫前期,在5%和10%假阳性率下检出率均为85%;晚发型子痫前期筛查性能明显较差。
要点
- 联合母体特征、血清生物标志物和子宫动脉搏动指数筛查早发型子痫前期,5%和10%假阳性率下检出率均为85%。
- 相同方案筛查孕37周前分娩的子痫前期,5%和10%假阳性率下检出率分别为52%和60%。
- 基于母体特征筛查晚发型子痫前期,5%和10%假阳性率下检出率分别为15%和48%;加用生物标志物未改善晚发型子痫前期检出率。
核心结论
- 孕11-13+6周基于母体特征和生物标志物筛查子痫前期,可在低假阳性率下获得高检出率,但晚发型子痫前期筛查性能明显较差。
- 本研究中估计胎盘体积和平均动脉压的效用有限,但需更大规模研究最终确定这些标志物的有效性。
研究设计与样本
- 前瞻性观察性非干预队列研究,在美国非选择性人群中开展。
- 纳入孕11-13+6周接受超声检查的患者,筛查1288例,最终1068例(82.99%)可用于分析。
主要发现
- 46例(4.3%)发生子痫前期,其中早发型子痫前期13例(1.22%),晚发型子痫前期33例(3.09%)。
- 联合母体特征、血清生物标志物和子宫动脉搏动指数,早发型子痫前期在5%或10%假阳性率下检出率均为85%。
- 相同方案筛查孕37周前分娩的子痫前期,5%和10%假阳性率下检出率分别为52%和60%。
- 基于母体特征筛查晚发型子痫前期,5%和10%假阳性率下检出率分别为15%和48%;筛查孕37周及以上分娩的子痫前期,检出率分别为24%和43%。
- 加用生物标志物未改善晚发型子痫前期及孕37周后分娩子痫前期的检出率。
临床怎么用
- 原文结论认为,孕11-13+6周基于母体特征和生物标志物筛查子痫前期与低假阳性率下的高检出率相关。
- 原文结论指出,晚发型子痫前期筛查性能明显较差。
- 原文结论指出,本研究中估计胎盘体积和平均动脉压的效用有限,需更大规模研究最终确定这些标志物的有效性。
局限性
- 原文结论指出,需更大规模研究最终确定估计胎盘体积和平均动脉压这些标志物的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia is a major cause of perinatal morbidity and mortality. First-trimester screening has been shown to be effective in selecting patients at an increased risk for preeclampsia in some studies. OBJECTIVE: We sought to evaluate the feasibility of screening for preeclampsia in the first trimester based on maternal characteristics, medical history, biomarkers, and placental volume. STUDY DESIGN: This is a prospective observational nonintervention cohort study in an unselected US population. Patients who presented for an ultrasound examination between 11-13+6 weeks' gestation were included. The following parameters were assessed and were used to calculate the risk of preeclampsia: maternal characteristics (demographic, anthropometric, and medical history), maternal biomarkers (mean arterial pressure, uterine artery pulsatility index, placental growth factor, pregnancy-associated plasma protein A, and maternal serum alpha-fetoprotein), and estimated placental volume. After delivery, medical records were searched for the diagnosis of preeclampsia. Detection rates for early-onset preeclampsia (<34 weeks' gestation) and later-onset preeclampsia (≥34 weeks' gestation) for 5% and 10% false-positive rates using various combinations of markers were calculated. RESULTS: We screened 1288 patients of whom 1068 (82.99%) were available for analysis. In all, 46 (4.3%) developed preeclampsia, with 13 (1.22%) having early-onset preeclampsia and 33 (3.09%) having late-onset preeclampsia. Using maternal characteristics, serum biomarkers, and uterine artery pulsatility index, the detection rate of early-onset preeclampsia for either 5% or 10% false-positive rate was 85%. With the same protocol, the detection rates for preeclampsia with delivery <37 weeks were 52% and 60% for 5% and 10% false-positive rates, respectively. Based on maternal characteristics, the detection rates for late-onset preeclampsia were 15% and 48% for 5% and 10%, while for preeclampsia at ≥37 weeks' gestation the detection rates were 24% and 43%, respectively. The detection rates for late-onset preeclampsia and preeclampsia with delivery at >37 weeks' gestation were not improved by the addition of biomarkers. CONCLUSION: Screening for preeclampsia at 11-13+6 weeks' gestation using maternal characteristics and biomarkers is associated with a high detection rate for a low false-positive rate. Screening for late-onset preeclampsia yields a much poorer performance. In this study the utility of estimated placental volume and mean arterial pressure was limited but larger studies are needed to ultimately determine the effectiveness of these markers.
引用
- Sonek J, Krantz D, Carmichael J, et al. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume. Am J Obstet Gynecol. 2017. PMID: 29097177. doi:10.1016/j.ajog.2017.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。